A clear comparison
BPC-157 and TB-500 are different peptides that appear in recovery discussions. BPC-157 is associated with tissue-repair models; TB-500 requires careful distinction from full-length thymosin beta-4.
The differences at a glance
The studies used different materials and measured different outcomes. They cannot establish whether BPC-157 or TB-500 performs better for recovery.
Reference facts and current product information are separate below. On a small screen, swipe within the table; keyboard users can focus it and scroll with the arrow keys.
| Compare | BPC-157 | TB-500 | Wolverine |
|---|---|---|---|
| Reference · material class | Single peptide | Single peptide | Two-peptide blend |
| Reference · identity and composition | BPC-157. Supplied form and exact specification require matching documentation. | TB-500. Supplied form and exact specification require matching documentation. | BPC-157 + TB-500. Individual component quantities are unconfirmed. |
| Reference · research question | Recovery & gut | Repair & recovery | BPC-157 + TB-500 |
| Reference · evidence and limitations | Much of the repair literature comes from cells and animal models. A tendon-cell experiment can help explain a mechanism; it cannot establish a human recovery timeline. | TB-500 is a commercial name used for materials associated with thymosin beta-4. Published work on full-length thymosin beta-4 does not automatically apply to a fragment sold as TB-500. Check the supplied sequence. | The listed 20 mg is the nominal total blend amount. The ingredient split is not confirmed here, so it should not be assumed to contain 10 mg of each peptide. |
| Reference · source papers | Chang et al. (2011): BPC-157 and tendon fibroblast experiments | Esposito et al. (2012): analytical identification of the TB-500 fragment | See the ingredient-specific sources and limitations in the comparison. |
| Product · current sizes and prices | 10 mg · $69.99 In stock | 5 mg · $49.99 In stock10 mg · $74.99 In stock | 10 mg · $79.99 In stock20 mg · $119.99 In stock |
| Product · current stock | In stock | In stock | In stock |
| Product · supplied specification | Confirm form, identity and specification for the selected size. A field not reported remains unconfirmed. Product specifications | Confirm form, identity and specification for the selected size. A field not reported remains unconfirmed. Product specifications | Confirm form, identity and specification for the selected size. A field not reported remains unconfirmed. Product specifications |
| Product · matching lot records | No matching published record. Check Lab Results | No matching published record. Check Lab Results | No matching published record. Check Lab Results |
| Product · information and availability | View available options | View available options | View available options |
Product figures come from the current WooCommerce listing in the store currency. Package milligrams are nominal material amounts, not doses. No report for another sample or lot is substituted for a matching record.
The difference in plain language
BPC-157 is a 15-amino-acid peptide. Researchers have examined cell movement and responses in tendon and other tissue models. TB-500 is a commercial label associated with thymosin beta-4 materials. Before comparing mechanisms, establish whether the paper and the supplied material refer to the same sequence. A shared recovery category does not make the two compounds interchangeable.
Why people compare them
Searches about tendon repair, ligament recovery and healing often bring these names together. These are useful starting interests, but the evidence needs a narrower question. A study measuring fibroblast migration asks how particular cells move under experimental conditions. It does not measure how soon a person can return to training. Look for the tissue, the model and the measured endpoint before interpreting a headline.
Single compounds or Wolverine?
Separate product listings make it easier to compare identity, size and price for each compound. Wolverine combines the two names in one blend. A blend introduces another question: the amount of each ingredient. The current Wolverine listing confirms the components and 20 mg nominal total, but not the split. It is therefore not possible to calculate its BPC-157 content from the total alone.
What the original papers can tell you
The BPC-157 tendon paper listed below reports preclinical experiments. The TB-500 paper is an analytical identification study of an acetylated fragment, rather than a demonstration of recovery benefits. Keeping those study types separate produces a much more useful comparison than assigning both products a generic healing score. Open the existing product overview for the longer scientific discussion.
Common questions
Is TB-500 the same as BPC-157?
No. They have different identities and research backgrounds. A common recovery interest does not make them substitutes.
Is Wolverine stronger than either one?
Its total package amount cannot establish potency or benefit. Component quantities and evidence for the exact blend would be needed.
Original sources
These papers support the specific mechanisms or study models discussed above. They do not test the current Peptide Place catalogue batches.
- Chang et al. (2011): BPC-157 and tendon fibroblast experiments ↗
- Esposito et al. (2012): analytical identification of the TB-500 fragment ↗
Continue exploring
BPC-157: current options and full overview →
TB-500: current options and full overview →
Molecular identity: start before the outcome
BPC-157 is described as a 15-amino-acid peptide. Thymosin beta-4 is a different, longer peptide. TB-500 needs another check: the commercial name alone does not establish whether a material is a particular fragment, full-length thymosin beta-4 or something else. A comparison needs the actual molecular identity.
Why the fragment distinction matters
Esposito and colleagues identified an N-terminally acetylated fragment corresponding to residues 17–23 of thymosin beta-4 in a TB-500 product. They used chromatographic and mass-spectrometric methods. This was an analytical identification study, not a trial of recovery in people. Its finding also does not identify every product sold under that name. Read the original 2012 paper.
A fragment is a selected part of a longer chain. An acetyl group is a chemical modification at one end. Those details can affect what a method detects and which paper is relevant. A result for the full peptide should not be assigned to a fragment just because the names appear together.
What did the tissue experiments measure?
Chang and colleagues examined BPC-157 using rat tendon explants and cultured tendon fibroblasts. An explant is a piece of tissue maintained outside the animal; a fibroblast is a cell involved in making and maintaining connective tissue. The researchers examined cell movement, outgrowth and related signalling. These endpoints do not measure a person’s return to sport. Read Chang et al. (2011).
Comparing different experiments fairly
Before comparing a BPC-157 finding with a thymosin beta-4 or TB-500 finding, match the species, tissue, material and endpoint. Cell migration in one experiment and wound closure in another are not a head-to-head test. The direction of two favourable results does not establish which compound performs better.
Our BPC-157 tendon research guide follows the tissue-specific question. The TB-500 research profile explains the naming issue in more detail.
Analytical checks that support a comparison
Chromatography separates components in a sample. Mass spectrometry examines mass-related signals that can help assess identity. A purity percentage alone does not tell you which sequence was supplied, how much peptide is present or whether it matches the published experiment.
Ask whether the report identifies the sample, lot, expected material and method. Then check whether the method is suitable for the claimed identity. See HPLC versus LC-MS peptide testing for the practical difference.
Can these studies identify a better recovery peptide?
They support specific experimental questions. The studies described here do not provide a direct human comparison of recovery, long-term safety or return to activity. A useful comparison keeps those unanswered questions visible alongside the interesting biology.
Use the same questions for both sides
Keep molecular identity, model and endpoint in separate columns. The research-comparison worksheet helps avoid treating unlike studies as a head-to-head trial. For the analytical part, separate purity from content.

